Publication | Closed Access

Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers

Molecular PharmacologyMedicineHealthy VolunteersMultiple-dose StudyClinical PharmacologyPharmacotherapyDrug DevelopmentNovel Nav1.7 InhibitorPharmacologyNovel TherapyDrug Discovery